160 related articles for article (PubMed ID: 32686223)
1. Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018.
Brown JR; Oh G; Wang Y; Slavova S; Delcher C; Dasgupta N; Freeman PR
J Rural Health; 2021 Jan; 37(1):23-28. PubMed ID: 32686223
[TBL] [Abstract][Full Text] [Related]
2. Controlled Substance Prescribing Patterns--Prescription Behavior Surveillance System, Eight States, 2013.
Paulozzi LJ; Strickler GK; Kreiner PW; Koris CM;
MMWR Surveill Summ; 2015 Oct; 64(9):1-14. PubMed ID: 26469747
[TBL] [Abstract][Full Text] [Related]
3. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
4. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
5. Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
Cassidy TA; DasMahapatra P; Black RA; Wieman MS; Butler SF
Pain Med; 2014 Mar; 15(3):440-51. PubMed ID: 24330279
[TBL] [Abstract][Full Text] [Related]
6. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.
Cohen JP; Mendoza M; Roland C
Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162
[TBL] [Abstract][Full Text] [Related]
7. Trends and Patterns of Opioid Analgesic Prescribing: Regional and Rural-Urban Variations in Kentucky From 2012 to 2015.
Luu H; Slavova S; Freeman PR; Lofwall M; Browning S; Bush H
J Rural Health; 2019 Jan; 35(1):97-107. PubMed ID: 29664203
[TBL] [Abstract][Full Text] [Related]
8. Opioids with abuse-deterrent properties: A regulatory and technological overview.
Haddox JD
J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
[TBL] [Abstract][Full Text] [Related]
9. Opioid Prescribing Behaviors - Prescription Behavior Surveillance System, 11 States, 2010-2016.
Strickler GK; Kreiner PW; Halpin JF; Doyle E; Paulozzi LJ
MMWR Surveill Summ; 2020 Jan; 69(1):1-14. PubMed ID: 31999681
[TBL] [Abstract][Full Text] [Related]
10. Postmarketing Analysis of Misuse, Abuse, and Diversion of Xtampza ER.
Geoffrey Severtson S; Kreider SED; Amioka EC; Margolin ZR; Iwanicki JL; Dart RC
Pain Med; 2020 Dec; 21(12):3660-3668. PubMed ID: 33094329
[TBL] [Abstract][Full Text] [Related]
11. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
Vosburg SK; Haynes C; Besharat A; Green JL
Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
[TBL] [Abstract][Full Text] [Related]
12. Associations between statewide prescription drug monitoring program (PDMP) requirement and physician patterns of prescribing opioid analgesics for patients with non-cancer chronic pain.
Lin HC; Wang Z; Boyd C; Simoni-Wastila L; Buu A
Addict Behav; 2018 Jan; 76():348-354. PubMed ID: 28898808
[TBL] [Abstract][Full Text] [Related]
13. Effects of mandatory prescription drug monitoring program (PDMP) use laws on prescriber registration and use and on risky prescribing.
Strickler GK; Zhang K; Halpin JF; Bohnert ASB; Baldwin GT; Kreiner PW
Drug Alcohol Depend; 2019 Jun; 199():1-9. PubMed ID: 30954863
[TBL] [Abstract][Full Text] [Related]
14. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States.
Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F
Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498
[TBL] [Abstract][Full Text] [Related]
15. Time trends and prescribing patterns of opioid drugs in UK primary care patients with non-cancer pain: A retrospective cohort study.
Jani M; Birlie Yimer B; Sheppard T; Lunt M; Dixon WG
PLoS Med; 2020 Oct; 17(10):e1003270. PubMed ID: 33057368
[TBL] [Abstract][Full Text] [Related]
16. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
Rauck RL
Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
[TBL] [Abstract][Full Text] [Related]
17. Development and impact of prescription opioid abuse deterrent formulation technologies.
Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
[TBL] [Abstract][Full Text] [Related]
18. ADF: Abuse-Deterrent Formulation or Another Disillusioned Formulation?
Brooks A; Kominek C
Pain Med; 2018 May; 19(5):907-909. PubMed ID: 29025056
[No Abstract] [Full Text] [Related]
19. Four States With Robust Prescription Drug Monitoring Programs Reduced Opioid Dosages.
Haffajee RL; Mello MM; Zhang F; Zaslavsky AM; Larochelle MR; Wharam JF
Health Aff (Millwood); 2018 Jun; 37(6):964-974. PubMed ID: 29863921
[TBL] [Abstract][Full Text] [Related]
20. The effects of state rules on opioid prescribing in Indiana.
Al Achkar M; Grannis S; Revere D; MacKie P; Howard M; Gupta S
BMC Health Serv Res; 2018 Jan; 18(1):29. PubMed ID: 29347984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
